N/A
Completed N=123
Observational Study With PASCALLERG ® in Patients With Hay Fever
Source: ClinicalTrials.gov NCT01660737 ↗Enrolled (actual)
123
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Efficacy of Pascallerg — 60; 44; 15; 2 participants
Summary
The aim of this observational study is to document the therapeutic use of PASCALLERG ® for hay fever. Based on the survey is a decrease in disease-specific symptoms when taking PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility can be assessed.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy of Pascallerg |
60; 44; 15; 2; 2 | — |
| PRIMARY Tolerability of Pascallerg |
122; 1 | — |
| SECONDARY Numerical Rating Scale Well Beeing (Pre- Post) |
109; 4; 2 | — |
| SECONDARY Change of Symptom Dry Eyes (Pre- Post) |
36; 9; 0 | — |
| SECONDARY Change of Symptom Itching Eyes (Pre- Post) |
87; 10; 4 | — |
| SECONDARY Change of Symptom Burning Eyes (Pre-post) |
68; 6; 2 | — |
| SECONDARY Change of Symptom Bronchial Complaints (Pre-post) |
44; 7; 3 | — |
| SECONDARY Change of Symptom Sneezing (Pre-post) |
87; 13; 7 | — |
| SECONDARY Change of Symptom Rhinitis (Pre-post) |
89; 8; 5 | — |
| SECONDARY Change of Symtom Fatigue / Tiredness |
77; 11; 5 | — |
| SECONDARY Change of Symptom Headache (Pre-post) |
38; 15; 0 | — |
| SECONDARY Change of Symptom Tearing Eyes (Pre-post) |
70; 7; 5 | — |
Eligibility Criteria
Inclusion Criteria
- hay fever
Exclusion Criteria
- Lactose intolerance and / or
- Chromium hypersensitivity
Data sourced from ClinicalTrials.gov (NCT01660737). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.